Bio-Gene Technology Ltd. Statistics
Want to see AU:BGT full AI Analyst Report?
Bio-Gene Technology Ltd. (BGT) Stock Statistics & Valuation Metrics
Total Valuation
Bio-Gene Technology Ltd. has a market cap or net worth of AUD 7.01M. The enterprise value is AUD 4.07M.
- Market Cap
- AUD 7.01M
- Enterprise Value
- AUD 4.07M
Share Statistics
Bio-Gene Technology Ltd. has 438,061,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 438,061,100
- Owned by Insiders
- 0.85%
- Owned by Institutions
- ―
Financial Efficiency
Bio-Gene Technology Ltd.’s return on equity (ROE) is -1.11 and return on invested capital (ROIC) is -135.48%.
- Return on Equity (ROE)
- -1.11
- Return on Assets (ROA)
- -0.89
- Return on Invested Capital (ROIC)
- -135.48%
- Return on Capital Employed (ROCE)
- -1.63
- Revenue Per Employee
- 0
- Profits Per Employee
- -466.16K
- Employee Count
- 5
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Bio-Gene Technology Ltd. is -2.13. Bio-Gene Technology Ltd.’s PEG ratio is -0.10.
- PE Ratio
- -2.13
- PS Ratio
- 0.00
- PB Ratio
- 2.42
- Price to FCF
- -2.23
- Price to Operating Cash Flow
- -2.61
- PEG Ratio
- -0.10
Income Statement
In the last 12 months, Bio-Gene Technology Ltd. had revenue of 0 and earned -2.33M in profits. Earnings per share was -0.01.
- Revenue
- 0
- Gross Profit
- -42.00K
- Operating Income
- -3.41M
- Pretax Income
- -2.80M
- Net Income
- -2.33M
- EBITDA
- -3.36M
- Earnings Per Share (EPS)
- -0.01
Cash Flow
In the last 12 months, operating cash flow was -1.94M and capital expenditures -4, giving a free cash flow of -1.94M billion.
- Operating Cash Flow
- -1.94M
- Free Cash Flow
- -1.94M
- Free Cash Flow per Share
- -0.01
Dividends & Yields
Bio-Gene Technology Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -44.84%
- Earnings Yield
- -46.05%
Stock Price Statistics
- Beta
- 0.31
- 52-Week Price Change
- -42.86%
- 50-Day Moving Average
- 0.01
- 200-Day Moving Average
- 0.02
- Relative Strength Index (RSI)
- 68.15
- Average Volume (3m)
- 321.11K
Important Dates
Bio-Gene Technology Ltd. upcoming earnings date is Mar 03, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 28, 2026
- Next Earnings Date
- Mar 03, 2027
- Ex-Dividend Date
- ―
Financial Position
Bio-Gene Technology Ltd. as a current ratio of 4.78, with Debt / Equity ratio of 0.00%
- Current Ratio
- 4.78
- Quick Ratio
- 4.78
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.58
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Bio-Gene Technology Ltd. has paid -469.50K in taxes.
- Income Tax
- -469.50K
- Effective Tax Rate
- 0.17
Enterprise Valuation
Bio-Gene Technology Ltd. EV to EBITDA ratio is -0.71, with an EV/FCF ratio of -1.23.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.71
- EV to Free Cash Flow
- -1.23
- EV to Operating Cash Flow
- -1.23
Balance Sheet
Bio-Gene Technology Ltd. has AUD 1.94M in cash and marketable securities with AUD 0.00 in debt, giving a net cash position of AUD 1.94M billion.
- Cash & Marketable Securities
- AUD 1.94M
- Total Debt
- AUD 0.00
- Net Cash
- AUD 1.94M
- Net Cash Per Share
- AUD 0.00
- Tangible Book Value Per Share
- AUD 0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Bio-Gene Technology Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 38.52%
Scores
- Smart Score
- 2
- AI Score
- 44
